Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "outlook," "plan," "predict," "should," "will," and ...

CWAN Investor Day September 3, 2025 NYSE, NYC Safe Harbor This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include the following factors in reference to Clearwater (including its recently completed acquisitions), our possible o ...

Company Strategy & Growth Model - Amphastar operates with a "Three-H Focus" on High Quality, High Efficiency, and High Technology to drive pipeline development and achieve high net income margins[8, 15, 17] - The company employs a dual-strategy growth model, combining organic pipeline development with strategic acquisitions[8, 13, 14] - Amphastar is transitioning towards proprietary and biosimilar drugs, projecting a shift from 63% generic, 16% biosimilar, and 21% proprietary in 2021 to 15% generic, 35% biosimilar, and 50% proprietary in 2026[19, 20] Financial Performance - Amphastar's revenue has grown steadily, reaching $732 million in 2024[15, 54] - Adjusted net income margin has increased significantly from 3.5% in 2018 to 27.4% in 2024[15] - The company has invested approximately $351 million in self-funded R&D over the recent 5 years[26] Pipeline Development - Amphastar has a diverse pipeline of ANDAs and BLAs with technical barriers, including 6 generic candidates and 1 biosimilar candidate[29] - The company is developing an interchangeable insulin pipeline, covering the full spectrum of insulin from rapid to long-acting[31, 32] - Amphastar in-licensed 3 new peptide assets (AMP-105, AMP-107, AMP-109) targeting oncology and ophthalmology with a market potential of >$50 billion and >$10 billion respectively[34, 44] Key Products - BAQSIMI® sales are projected to reach a peak of $250 million to $275 million, with an estimated incremental adjusted EPS of $2.00 to $2.50 at peak[61, 66] - BAQSIMI® worldwide annual sales reached $166 million in 2024[65] - Primatene MIST® sales surpassed $100 million in 2024[69]

September 3, 2025 Barclays Global Consumer Staples Conference 2025 Kevin Hourican CHAIR OF THE BOARD AND CHIEF EXECUTIVE OFFICER 3 Forward-Looking Statements Statements made in this presentation that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements concern, among other things, our future financial performance and results, business strategy, plans, goals and objectives, ...

Fiscal Third Quarter 2025 Highlights - REV Group experienced momentum in year-over-year throughput increases[7] - The company broke ground for a $20 million investment in the Brandon, SD facility[7] - REV Group completed the sale of Lance Camper[7] - The company demonstrated strong cash generation and a solid balance sheet position[7] - REV Group raised its fiscal year 2025 outlook[7] Third Quarter Fiscal 2025 Consolidated Results - Net sales increased to $644.9 million in Q3 2025, compared to $579.4 million in Q3 2024[9], a $109.7 million or 20.5% increase excluding Bus Manufacturing Businesses[13] - Adjusted EBITDA increased to $64.1 million in Q3 2025, compared to $45.2 million in Q3 2024[9], a $25.5 million or 66.1% increase excluding Bus Manufacturing Businesses[13] Full Year Fiscal 2025 Outlook - REV Group updated its net sales guidance to $2.40 to $2.45 billion, compared to the prior guidance of $2.35 to $2.45 billion and the 2024 actual of $2.38 billion[27] - The company updated its Adjusted EBITDA guidance to $220 to $230 million, compared to the prior guidance of $200 to $220 million and the 2024 actual of $162.8 million[27] - REV Group updated its Free Cash Flow guidance to $140 to $150 million, compared to the prior guidance of $100 to $120 million[27] Balance Sheet & Other Financial Items - Year-to-date cash from operations totaled $164.2 million[25] - Net debt was $54.0 million[25] - Trade working capital decreased by $56.6 million compared to 4Q24[26] - $117.6 million cash was returned to shareholders year to date[26]

Market Opportunity - The US bunion market represents a significant opportunity, with approximately 65 million Americans affected by bunions [9] - Of those affected, 44 million seek medical treatment annually [9] - The current US market for bunion surgical procedures is estimated at $23 billion, with a potential to exceed $5 billion [9] - Approximately 450,000 surgical procedures are performed annually, while an estimated 650,000 additional patients are in need of surgical treatment [9] Treace Medical Concepts' Position - Treace Medical Concepts, Inc is focused on improving outcomes for bunion patients, with a 5-year revenue CAGR of 40% [7] - The company's FY 2024 revenue reached $2094 million, representing a 12% increase, with a gross margin of 80% [7] - Approximately one-third of US foot surgeons are currently using Lapiplasty [7] Technology and Innovation - Treace is the pioneer and leader in 3D bunion surgery, protected by 117 US patents and pending patents [7] - Lapiplasty has demonstrated early weight bearing at an average of 77 days in a walking boot [19] - Lapiplasty has demonstrated 81% pain reduction with 89% improvement in MOxFQ walking/standing scores at 48 months [19] - Lapiplasty has demonstrated low recurrence rates of 08% (HVA >20°) & 84% (HVA >15°) at 48 months [19]

CAPITAL MARKETS DAY September 3, 2025 B E N S O N Q U A R R Y ‖ B E N S O N , N O R T H C A R O L I N A 2025 Capital Markets Day 2 Statement Regarding Safe Harbor for Forward-Looking Statements Investors are cautioned that all statements herein that relate to the future involve risks and uncertainties and are based on assumptions that the Company believes in good faith are reasonable but which may be materially different from actual results. These statements, which are forward-looking statements under the P ...

Financial Performance & Outlook - Net sales increased by 1.0% in Q2 2025[11] - Organic sales increased by 1.8% in Q2 2025, including a 0.6% negative impact from lower private label pet sales[11] - Base Business EPS increased by 1% in Q2 2025[11] - The company projects net sales growth to be up low single digits for 2025, including a flat to low-single-digit negative impact from foreign exchange[16] - The company anticipates organic sales growth to be at the low end of 2% to 4% for 2025, including the impact of exiting private label pet sales[16] Strategic Initiatives - A new three-year productivity program is projected to result in cumulative pre-tax charges totaling between $200 and $300 million[13] - The company's 2025 strategic plan focuses on delivering science-led innovation and improving capabilities in digital, data, creative, and RGM (Revenue Growth Management)[40] - The company scaled its automated RGM diagnostic tool to cover 78% of net sales[71] Innovation & Product Relaunches - Colgate Strong Teeth was relaunched in India with a new formulation in 2025, featuring Calcium Boost + Arginine technology for 2x stronger teeth[49, 51] - EltaMD UV Skin Recovery features a patented Skin Barrier Repair Technology, AAComplex, and showed a 52% reduction in visible redness in clinical studies[58, 61] Future Strategy - The company is accelerating change for its 2030 strategy, focusing on leveraging global reach, science-based innovation, omni-channel demand generation, and data/analytics/AI capabilities[80, 81]

Investor Presentation Company Overview September 3, 2025 1 Disclaimer Forward-Looking Statements This presentation includes statements that express our management's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements." These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "ant ...

Financial Performance - Great Elm achieved record results in Fiscal Q4 2025, marking the best operating quarter and fiscal year in its history[6] - Fee-paying assets under management (FPAUM) grew by 5% year-over-year as of June 30, 2025[6] - Book value per share increased by 24% from the prior year, reaching $2.65[6] - Fiscal 4Q25 revenue was $5.6 million, with revenue growth over 140% excluding a prior-year BTS property sale[34] - Assets Under Management ("AUM") as of June 30, 2025, was $759 million, up 4% from June 30, 2024[40] - Fee-Paying AUM ("FPAUM") as of June 30, 2025, was $553 million, up 5% from June 30, 2024[42] Strategic Initiatives - Great Elm launched Monomoy Construction Services, LLC ("MCS") in February 2025, expanding its real estate platform[6] - A strategic partnership with Kennedy Lewis Investment Management ("KLIM") was announced in July 2025, providing up to $150 million in leverageable capital[6] - Woodstead Value Fund, L.P ("Woodstead") purchased 4 million shares of GEG at $2.25 per share for gross proceeds of $9 million in August 2025[6] - GECC sold 1.3 million shares to an affiliate of Booker Smith, or 9.9% of outstanding common stock, at $11.65 per share for gross proceeds of $15 million[6] Capital Allocation - The Board of Directors authorized an additional $5 million of stock repurchases, bringing the total stock repurchase program to $25 million[6]